This week, the PAX-D Trial screened its 200th participant to take part in the study!
We'd like to thank our study teams across all nine PAX-D sites for their hard work getting the trial to this milestone.
Consenting to take part in the trial means a participant has read our Participant Information Sheet and has agreed to enter into the run-in phase ahead of randomisation, which is when they will be allocated to either the pramipexole condition or a placebo.
Although trial recruitment is winding down in the final few months of the trial, some PAX-D trial sites are still looking for participants to screen. If you are interested in taking part, please follow this link to find out more about our trial sites around the country.
